The fibrin-specific plasminogen activator – which is already sold as Metalyse and TNKase for patients with suspected acute myocardial infarction – was being tested in phase 3 stroke trials ...
Genentech has won FDA approval for its clot-buster TNKase as a treatment for acute ischaemic stroke, after almost abandoning the project in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback